A phase I study of the safety, tolerability, pharmacokinetics, and immunoregulatory activity of urelumab (BMS-663513) in subjects with advanced and/or metastatic solid tumors and relapsed/refractory B-cell non-Hodgkin's lymphoma (B-NHL) Meeting Abstract
| Authors: | Melero, I.; Gangadhar, T. C.; Kohrt, H. E.; Segal, N. H.; Logan, T.; Urba, W. J.; Hodi, F. S.; Ott, P. A.; Perez-Gracia, J. L.; Wolchok, J. D.; Shah, A.; Kurland, J. F.; Cohen, L. J.; Levy, R.; Wigginton, J. M.; Goldberg, S. M. |
| Abstract Title: | A phase I study of the safety, tolerability, pharmacokinetics, and immunoregulatory activity of urelumab (BMS-663513) in subjects with advanced and/or metastatic solid tumors and relapsed/refractory B-cell non-Hodgkin's lymphoma (B-NHL) |
| Meeting Title: | 49th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 31 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2013 May 31-Jun 4 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2013-05-20 |
| Language: | English |
| ACCESSION: | WOS:000335419605401 |
| PROVIDER: | wos |
| DOI: | 10.1200/jco.2013.31.15_suppl.TPS3107 |
| Notes: | Meeting Abstract: TPS3107 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work